Veracyte, Inc. (VCYT): Total Assets
$1.41B
As of 2025-12-31
$1.49B
As of 2026-06-30
+6.7%
3-year compound annual growth
+25.2%
5-year compound annual growth
+34.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.41B | +8.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.30B | +16.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.11B | -3.6% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $1.16B | -2.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $1.19B | +159.8% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $457.16M | +66.1% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $275.21M | +128.1% | 2021-02-22, Balance as of period end |
| 2018-12-31 | $120.64M | +53.3% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $78.67M | -22.1% | 2019-02-25, Balance as of period end |
| 2016-12-31 | $101.03M | +34.3% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $75.25M | +16.1% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $64.84M | -18.6% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $79.63M | +317.6% | 2015-03-25, Balance as of period end |
| 2012-12-31 | $19.07M | n/a | 2014-03-20, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 2025-12-31 | $1.41B | +8.2% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $413.23M | -15.8% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $578.56M | +8.9% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $1.13B | +227.5% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $1.21B | -0.5% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $632.65M | +109.4% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $2.01B | +35.5% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $2.92B | -2.1% |
| RadNet, Inc. (RDNT) | 2025-12-31 | $3.76B | +14.4% |
Compare VCYT, CDNA, CSTL, CAI side by side · Screen every company in Services-Medical Laboratories ↗